Drugs in MeSH Category Anti-Ulcer Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	FAMOTIDINE	famotidine	TABLET;ORAL	216441-002	Jun 3, 2022	AB	RX	No	No
Natco	LANSOPRAZOLE	lansoprazole	CAPSULE, DELAYED REL PELLETS;ORAL	203306-001	Jan 13, 2016		OTC	No	No
Vkt Pharma	FAMOTIDINE	famotidine	TABLET;ORAL	215630-001	Jan 7, 2022	AB	RX	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Anti-Ulcer Agents

Last updated: January 21, 2026

Executive Summary

The anti-ulcer agent market is characterized by rapid innovation, significant patent activity, and evolving regulatory landscapes. This report examines current market dynamics, patent filing trends, key players, and future prospects. It identifies notable shifts toward novel mechanisms of action, the impact of generics, and technological advancements influencing patent strategies. Key stakeholders include established pharmaceutical companies, generic drug manufacturers, and biotech firms. Patent landscapes reveal a concentration of filings around acid suppression, mucosal protection, and Helicobacter pylori eradication therapies. The analysis underscores the importance of strategic patenting to maintain market exclusivity amid patent expirations and biosimilar emergence.

---

What is the Scope of the Anti-Ulcer Agents Market?

Definition and Classification

Anti-ulcer agents, as classified in the Medical Subject Headings (MeSH) of the National Library of Medicine (NLM), encompass medications designed to prevent or treat gastric and duodenal ulcers, gastroesophageal reflux disease (GERD), and related mucosal injuries.

Subcategories	Main Drugs	Mechanism of Action
Proton Pump Inhibitors (PPIs)	Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole	Suppress gastric acid by inhibiting H+/K+ ATPase enzyme
H2 Receptor Antagonists	Ranitidine, Famotidine, Cimetidine, Nizatidine	Block histamine H2 receptors to reduce acid secretion
Mucosal Protective Agents	Sucralfate, Bismuth compounds	Create protective barriers over ulcers
Antibiotics for H. pylori	Clarithromycin, Amoxicillin, Metronidazole, Levofloxacin	Eradicate Helicobacter pylori, reducing ulcer risk

Market Size and Growth Overview

• Global valuation (2022): Approx. $7.5 billion [1]
• Projected CAGR (2023-2028): ~4.2%, driven by rising GERD prevalence and aging populations
• Key markets: North America (~40%), Europe (~25%), Asia-Pacific (~20%), Rest of world (~15%)

---

How Do Market Dynamics Drive Innovation in Anti-Ulcer Drugs?

Drivers of Innovation

Factor	Impact	Example/Trend
Increasing prevalence of GERD and peptic ulcers	Stimulates demand for novel therapies	Improved formulations targeting resistant ulcers
Rising resistance to antibiotics	Fuels development of alternative agents	Probiotics, bioengineered peptides
Safety concerns with existing drugs	Push for safer drugs	PPIs linked with long-term risks (bone fracture, renal issues)
Advances in molecular biology	Enable targeted therapy development	CRISPR, monoclonal antibodies

Challenges in Market Growth

• Patent expirations of leading PPIs (e.g., omeprazole in 2010s) causing generic erosion
• Concerns over long-term safety profiles
• Competition from over-the-counter (OTC) formulations

Competitive Landscape

Major Companies	Key Patents and Innovations	Notable Strategies
AstraZeneca	Esomeprazole patents (2001)	Focused on pharmacokinetics and formulation improvements
Takeda Pharmaceuticals	Protonix (pantoprazole)	Patent extensions using formulating techniques
GlaxoSmithKline	Ranitidine (withdrawn in 2020)	Transitioned to new H2 antagonists
Bayer	Bismuth compounds	Combination therapies for H. pylori

---

What Is the Patent Landscape for Anti-Ulcer Agents?

Patent Filing Trends

Time Period	Number of Patent Applications	Focus Areas	Source of Data
1990–2000	~1500	PPIs, H2 antagonists	Patent databases (USPTO, EPO)
2000–2010	~2200	Novel formulations, combinations, H. pylori eradication	WIPO, EPO, USPTO
2010–2020	~3000	Drug delivery, safety profiles, mechanism-specific patents	PatentScope, PATSTAT

Key Areas of Patent Focus

Patent Area	Description	Number of Patents (2020–2023)	Leading Assignees
Proton pump inhibitors modifications	New formulations and salts	1,200	AstraZeneca, Takeda, Bayer
H. pylori eradication combos	Novel antibiotic combinations	800	Johnson & Johnson, GSK
Mucosal protectants	Innovative delivery systems	600	Bayer, Teva
Long-acting formulations	Extended release/targeted delivery	400	Novartis, Boehringer Ingelheim

Key Patent Holders and Their Strategies

Company	Notable Patents	Strategy Focus	Patent Expiry Trends
AstraZeneca	Esomeprazole formulations (patent granted 2001, expiry 2022)	Renewal and combination therapies	Patent cliffs for primary drugs
Takeda	Proton pump inhibitor derivatives	Broad overlapping patents to extend exclusivity	Patents filed through 2025
GSK	Ranitidine formulations	Patent challenges and regulatory withdrawals	Declining patent filings post-2019
BAYER	Bismuth and combination agents	Formulation patents, delivery systems	Extending patent life through formulation patents

Patent Litigation and Patent Cliff

• Major drugs like omeprazole faced patent expiry after 2010, leading to significant generic infiltration.
• Patent litigation remains active, especially around formulations and delivery mechanisms to extend exclusivity.
• Recently, biosimilar attempts and regulatory delays have impacted market positioning.

---

How Are Regulatory Policies and Patent Strategies Intertwined?

Regulatory Frameworks Impacting Patent Strategy

Policy/Regulation	Effect on Patent Strategy	Notable Examples	Source
Patent Term Adjustment (U.S.)	Allows extensions for regulatory delays	U.S. Patent No. 6,820,328 (esomeprazole)	[2]
Supplementary Protection Certificates (EU)	Extend patent life by up to 5 years	European patent laws	[3]
Data Exclusivity Policies	Delay generic approval irrespective of patent status	U.S. Five-year data exclusivity	[4]
Biosimilar Patents	Need for specific patent claiming biosimilarity	Bylamintuzumab, Etanercept	[5]

Impact on Development and Market Entry

• Strategic patent filings ahead of patent expirations to maintain competitiveness.
• Filing for formulations and delivery platforms to extend patent life.
• Navigating regulatory pathways to avoid patent invalidation.

---

Future Outlook: Key Drivers and Challenges

Drivers	Challenges	Implication for Stakeholders
Innovation in targeted therapies	Patent expiration and biosimilar entry	Need for robust patent portfolios
Growing global burden of ulcers	Rising healthcare costs	Market expansion opportunities
Advances in nanotechnology and drug delivery	Regulatory approval complexities	Investment in delivery system patents

Projected Trends:

• Increased filings on long-acting and targeted delivery systems.
• Greater focus on combination therapies incorporating biologics.
• Rising importance of patent landscaping and defensive patenting strategies.

---

Comparison Table: Leading Anti-Ulcer Agents and Their Patent Status

Drug	Year Approved	Patent Expiry	Patent Focus	Next-generation Patents	Market Status
Omeprazole	1989	2010 (primary)	Formulation, salts	Yes, patents on new salts (2022)	Generic dominant post-expiry
Esomeprazole	2001	2022	Pure S-isomer, formulations	Multiple patents, extensions	Still under patent protection until 2023-2024
Rabeprazole	1999	2011	Novel salts, delivery systems	Some patents expired	Competition from generics
Pantoprazole	2000	2020	Drug delivery	Ongoing filings	Key patent expired, generic options now prevalent

---

Key Takeaways

• The anti-ulcer agent market remains dynamic, driven by innovation in formulations and delivery mechanisms.
• Patent activity is concentrated around PPIs, H. pylori eradication, and mucosal protection, with key patents expiring in the last decade leading to increased generic competition.
• Strategic patenting, including formulation improvements and combination therapies, remains essential for maintaining market exclusivity.
• Regulatory policies such as patent term extensions and data exclusivity significantly influence patent strategy.
• The future of the market hinges on developing safer, targeted, and long-acting therapies, supported by robust patent portfolios and navigating complex regulatory frameworks.

---

FAQs

Q1: How does patent expiration impact the market for anti-ulcer drugs?
Patent expiration opens the market to generics, reducing prices and market share for brand-name drugs. Companies tend to develop next-generation formulations and combination therapies to extend patent protection or replace expiring patents.

Q2: What are the recent innovations in anti-ulcer agent patents?
Recent innovations include long-acting formulations, targeted delivery systems, combination therapies with biologics, and drugs designed for resistant ulcers.

Q3: Who are the primary patent holders in the anti-ulcer drugs domain?
Major patent holders include AstraZeneca (esomeprazole), Takeda (pantoprazole derivatives), Bayer (bismuth and formulations), and various biotech firms focusing on delivery systems.

Q4: How do regulatory policies influence patent strategies?
Regulatory policies like patent term adjustments and exclusivity periods enable patent extensions, incentivizing companies to file for formulations and delivery innovations to prolong market exclusivity.

Q5: What are the future prospects for anti-ulcer agents?
The future involves developing safer, targeted, and longer-acting drugs, with patent strategies focusing on novel delivery technologies and combination therapies to sustain market exclusivity.

---

References

[1] Market Research Future. "Proton Pump Inhibitors Market Size, Share & Trends." 2022.
[2] U.S. Patent No. 6,820,328. "Proton pump inhibitors and methods," AstraZeneca, 2004.
[3] European Patent Office. "Supplementary Protection Certificates," 2021.
[4] U.S. Food and Drug Administration. "Drug Approvals and Data Exclusivity," 2023.
[5] WHO. "Biologic and Biosimilar Medical Products," 2021.